OptiNose (NSDQ:OPTN) raised $120 million with its initial public offering last week, adding $20 million to the target is set earlier this month. Yardley, Penn.-based OptiNose floated 7.5 million shares at $16 apiece in the offering, above the range it set Oct. 3 for 6.3 million shares at $15 to $17 apiece. Get the full story at our sister […]
OptiNose
OptiNose sets terms for $100m IPO
OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC. The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista Capital Partners intend to buy $25 million worth of shares as part of the offering, according to OptiNose. The company is slated to […]
OptiNose raises $37m in Series D for commercial efforts
OptiNose said today that it closed a $37 million Series D round led by Fidelity Management and Research Company. Avista Capital Partners, Entrepreneurs Fund and other current investors also contributed to the round. The Yardley, Penn.-based company said it plans to use the newly-acquired funds to support commercial development of its lead product candidate, OPN-375, […]
Baxter snags Medtronic vet Oesterle | Personnel Moves | February 14, 2017
Baxter (NYSE:BAX) announced earlier this month it tapped former Medtronic (NYSE:MDT) senior VP of medicine and tech Stephen Oesterle for its board of directors, bringing the total seats on the board to 12. Oesterle moved to the venture capital firm New Enterprise Associates last Sept from his position at Medtronic. Before moving to NEA, Oesterle served […]
OptiNose touts Phase III data for exhaled breath drug delivery
OptiNose touted data from a pair of Phase III clinical trials proving the safety and efficacy of its exhaled breath drug delivery treatment for chronic rhinosinusitis patients with and without polyps. The company presented the data today at the American Rhinologic Society’s annual meeting in San Diego. Data from both trials showed limited adverse effects from […]
